PENATALAKSANAAN HEPATITIS B : KAJIAN PUSTAKA
DOI:
https://doi.org/10.31004/jkt.v5i4.35930Keywords:
Hepatitis B, interferon, nukleosida, nukleotida, terapi farmakologiAbstract
Hepatitis B merupakan masalah kesehatan global yang serius, hepatitis B menyumbang sekitar 80% kasus karsinoma hepatoseluler primer dan menjadi penyebab kanker tertinggi kedua setelah rokok. Penatalaksanaan hepatitis B awalnya menggunakan interferon, kemudian hadir obat golongan baru yaitu analog nukelosida (NA) seperti lamivudin, dan seiring perkembangannya ditemukan obat baru seperti adefovir, entecavir, telbivudine dan tenofovir. Tingginya prevalensi infeksi hepatitis B sering kali berkaitan dengan rendahnya tingkat keberhasilan terapi pada pasien. Hasil pengobatan hepatitis B hingga saat ini masih belum memadai, sehingga beberapa kasus dapat berkembang menjadi sirosis hati dan kanker hati. Oleh karena itu, tinjauan ini membahas mengenai penatalaksanaan hepatitis B. Kajian pustaka dilakukan dengan penelusuran pustaka dengan pencarian online mengenai regimen terapi hepatitis B melalui situs pencarian Google, Google Scholar, Research Gate. Penelusuran pustaka menggunakan kata kunci “Treatment of Hepatitis B Article”. Terdapat perbedaan terapi pada hepatitis B akut dan kronik. Pada kondisi akut, tujuan terapi hepatitis B adalah untuk meningkatkan kenyamanan pasien. Sedangkan pada kondisi kronis, tujuan terapinya adalah untuk mengurangi risiko sirosis, kanker hati, dan meningkatkan kelangsungan hidup jangka panjang. Terapi farmakologi yang digunakan pada hepatitis B selama lima tahun terakhir yaitu golongan analog nukelosida, analog nukleotida dan interferon. Golongan analog nukleosida terdiri dari lamivudin, telbivudin, dan entecavir. Sedangkan golongan analog nukleotida terdiri dari tenofovir disoproxil fumarate, tenofovir alafenamid, dan adefovir.References
Alexopoulou, A., Vasilieva, L., & Karayiannis, P. (2020). New approaches to the treatment of chronic hepatitis B. Journal of Clinical Medicine, 9(10), 1–23. https://doi.org/10.3390/jcm9103187
Broquetas, T., & Carrión, J. A. (2022). Current Perspectives on Nucleos(t)ide Analogue Therapy for the Long-Term Treatment of Hepatitis B Virus. Hepatic Medicine: Evidence and Research, Volume 14(July), 87–100. https://doi.org/10.2147/hmer.s291976
Chien, R. N., & Liaw, Y. F. (2022). Current Trend in Antiviral Therapy for Chronic Hepatitis B. Viruses, 14(2). https://doi.org/10.3390/v14020434
Chuang, W. L., Jia, J., Chan, H. L. Y., Han, K. H., Tanwandee, T., Tan, D., Chen, X., Gane, E., Piratvisuth, T., Chen, L., Xie, Q., Sung, J. J. Y., Messinger, D., Wat, C., Bakalos, G., & Liaw, Y. F. (2018). Responses are durable for up to 5 years after completion of peginterferon alfa-2a treatment in hepatitis B e antigen-positive patients. Alimentary Pharmacology and Therapeutics, 47(9), 1306–1316. https://doi.org/10.1111/apt.14595
DiPiro, T, J., Yee, C, G., Posey, M, L., Haines, T, S., Nolin, D, T., Ellingrod, V. (2021). Pharmacotherapy: A Pathophysiologic Approach 11th Edition. McGraw-Hill: New York.
Fitriani, K. E., & Yulianti, T. (2022). EVALUASI TERAPI ANTIVIRAL PADA PASIEN HEPATITIS B KRONIS DI INSTALASI RAWAT INAP RSUD Dr. MOEWARDI SURAKARTA PERIODE JUNI TAHUN 2018-JUNI TAHUN 2019. Usadha Journal of Pharmacy, 123–137. https://doi.org/10.23917/ujp.v1i1.132
Gozali, A. P. (2020). Diagnosis, Tatalaksana dan Pencegahan Hepatitis B dalam Kehamilan. Cermin Dunia Kedokteran, 47(7), 354. https://doi.org/10.55175/cdk.v47i7.598
GUVENIR, M., & ARIKAN, A. (2020). Hepatitis b virus: From diagnosis to treatment. Polish Journal of Microbiology, 69(4), 391–399. https://doi.org/10.33073/PJM-2020-044
Hunou, F. A., Waleleng, B. J., & Rotty, L. W. A. (2022). Penatalaksanaan Hepatitis B pada Populasi Khusus. Medical Scope Journal, 4(1), 29–39. https://doi.org/10.35790/msj.v4i1.44645
Kurniawan, J. (2021). Perkembangan Terapi Hepatitis B Kronis di Indonesia. Jurnal Penyakit Dalam Indonesia, 8(3), 110. https://doi.org/10.7454/jpdi.v8i3.632
Moghadam, A. D., Eslami, P., Beirami, A. D., Iravani, S., Farokhi, E., Mansour-Ghanaei, A., Hashemi, M. R., Pasha, M. A., Mehrvar, A., & Nassiri-Toosi, M. (2021). An overview of the current hepatitis B treatment strategies after liver transplantation. Middle East Journal of Digestive Diseases, 13(1), 5–14. https://doi.org/10.34172/mejdd.2021.197
Nur Hidayah, A., & Afridah, W. (2023). Literature Review: Faktor Penyebab Hepatitis B Pada Ibu Hamil. Jurnal Multidisiplin Indonesia, 2(3), 443–450. https://doi.org/10.58344/jmi.v2i3.180
Ohsaki, E., Suwanmanee, Y., & Ueda, K. (2021). Chronic hepatitis b treatment strategies using polymerase inhibitor-based combination therapy. Viruses, 13(9). https://doi.org/10.3390/v13091691
Prifti, G. M., Moianos, D., Zoidis, G., Giannakopoulou, E., Pardali, V., & Tavis, J. E. (2021). Recent advances in hepatitis b treatment. Pharmaceuticals, 14(5), 1–27. https://doi.org/10.3390/ph14050417
Roediger, R., Smyth, E. K., & Dieterich, D. (2022). Adefovir for lamivudine-resistant hepatitis B. Antiviral Therapy, 27(1), 1–8. https://doi.org/10.1177/13596535211067605
Soi, V., Daifi, C., Yee, J., & Adams, E. (2019). Pathophysiology and Treatment of Hepatitis B and C Infections in Patients With End-Stage Renal Disease. Advances in Chronic Kidney Disease, 26(1), 41–50. https://doi.org/10.1053/j.ackd.2018.10.004
Stinco, M., Rubino, C., Trapani, S., Indolfi, G., & ORCID. (2021). Contents. World Journal of Gastroenterology, 9327(36).
Suk-Fong Lok, A. (2019). Hepatitis B Treatment: What We Know Now and What Remains to Be Researched. Hepatology Communications, 3(1), 8–19. https://doi.org/10.1002/hep4.1281
Thad Wilkins, Richard Sams, & Mary Carpenter. (2019). Hepatitis B: Screening, Prevention, Diagnosis, and Treatment. American Family Physician, 99(5), 314–323.
Thomas, D. L., Kiser, J. J., & Baum, M. M. (2022). Long-Acting Treatments for Hepatitis B. Clinical Infectious Diseases, 75(4 Supplement), S517–S524. https://doi.org/10.1093/cid/ciac718
Wikan Trisnaningtyas, R. (2017). Evaluasi Terapi Pada Pasien Hepatitis B Di Rsup Dr. Sardjito Yogyakarta. Jurnal Ilmiah Farmasi, 13(1), 27–33. https://doi.org/10.20885/jif.vol13.iss1.art5
Wong, W. W. L., Pechivanoglou, P., Wong, J., Bielecki, J. M., Haines, A., Erman, A., Saeed, Y., Phoon, A., Tadrous, M., Younis, M., Rayad, N. Z., Rac, V., Janssen, H. L. A., & Krahn, M. D. (2019). Antiviral treatment for treatment-naïve chronic hepatitis B: Systematic review and network meta-analysis of randomized controlled trials. Systematic Reviews, 8(1), 1–15. https://doi.org/10.1186/s13643-019-1126-1
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Malva Marshaniswa Yasykurah, Virga Fathiya Dalila, Baiq Dwiyan Nugrahani, Nanda Bulkis, Muhammad Naufal Farras Ananta, Nurhidayati
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
